Summary of subject disposition and demographic characteristics after oral administration of 200 or 500 μg of vilanterol or 200 μg of [14C]vilanterol to men
Subject disposition and demographic characteristics are summarized from two clinical studies. In the first tolerability study subjects received 200 or 500 μg of vilanterol. In the subsequent human radiolabel study, the subjects received 200 μg of [14C]vilanterol containing 74 kBq radioactivity.
| Characteristics | Tolerability Study GSK Study B2C106180 | Human Radiolabel Study GSK Study B2C106181 |
|---|---|---|
| Number of subjects completed: n | 9 | 6 |
| Oral administration | 200 or 500 μg of vilanterol | 200 μg of [14C]vilanterol |
| Age (yr): mean (range) | 33.1 (19–47) | 43.3 (35–53) |
| Race, n (%) | ||
| White/Caucasian/European | 7 (78) | 6 (100) |
| Asian | 1 (11) | |
| African American | 1 (11) | |
| Ethnicity, n (%) | ||
| Not Hispanic or Latino | 9 (100) | 6 (100) |
| Body mass index (kg/m2): mean (range) | 24.8 (21.3–29.0) | 26.2 (21.8–28.8) |
| Height (cm): mean (range) | 178 (166–186) | 179 (163–189) |
| Weight (kg): mean (range) | 78.5 (66.9–90.8) | 83.9 (57.8–102) |